making, using, selling, distributing, advertising,
exporting, offering for sale or dealing in Sitagliptin Phosphate Monohydrate
or any other salt of Sitagliptin in any form, alone ... licensee of plaintiff no.1 for marketing, distributing and selling Sitagliptin as
also Sitagliptin & Metformin combination in India, under the trade marks
ISTAVEL
Indian Patent No.209816 or any of the
claims thereof, including Sitagliptin or any of its
pharmaceutically acceptable salts such as Sitagliptin
Phosphate Monohydrate, including ... infringing
Sitagliptin drug products under the brand GLIPSIT-
M;
b. An order for damages in favour of the Plaintiffs and
against the Defendants as stated
that, in Merck v. Glenmark16 , though
the suit patent IN 816 claimed Sitagliptin and its pharmaceutically
acceptable salts, Sitagliptin phosphate monohydrate, though a salt ... Sitagliptin, was not claimed in IN 816, as it was not disclosed in the
said patent. What is claimed, therefore, he submits depends on what
) Boehringer Ingelheim Pharma vs Vee Excel Drugs And Pharmaceuticals ... on 2 June, 2022
Author: Ajay
needs;
(ii) that the molecule having International Non-Proprietary name of
"SITAGLIPTIN" was invented by the plaintiff Merck who has
patents ... under
the brand name "JANUVIA" and "JANUMET";
(iv) SITAGLIPTIN was approved for sale in United States of
America (USA) in October
having been issued by the plaintiffs in respect of a molecule name
Sitagliptin, the IUPAC name whereof is 7-[(3R)-3-Amino ... combination
with Metformin, is used to treat Diabetes Mellitus Type II. Sitagliptin,
as set out in the plaint, is a DPP-4 (di-peptidyl peptidase
defendant Glenmark Pharmaceuticals (hereafter
"Glenmark") from using its patented product Sitagliptin (Indian Patent No.
209816, hereafter "the patent ... patents in 102 countries for the suit patent
formulation i.e. the Sitagliptin molecule. The Indian Patent application was
filed on 06.01.2004; the international application
Astrazeneca Ab & Anr. vs Micro Labs Limited on 18 November, 2020
Author: Mukta Gupta
Merck v. Glenmark . The
claim in IN 816, as worded, encompassed
"Sitagliptin with its pharmaceutically
Signature Not Verified
Digitally Signed
By:DUSHYANT
RAWAL
Signing ... COMM) 178/2021 Page 26 of 86
acceptable salts". Sitagliptin Hydrochloride
was specifically exemplified in the complete
specifications
) Boehringer Ingelheim Pharma vs Vee Excel Drugs And Pharmaceuticals ... on 2 June, 2022
Author: Ajay
